中国中西医结合急救杂志
中國中西醫結閤急救雜誌
중국중서의결합급구잡지
INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE IN PRACTICE OF CRITICAL CARE MEDICINE
2014年
2期
81-83
,共3页
杨硕%罗光伟%胡小萍%万军%夏倩%陈菁%袁文胜%孙洁民
楊碩%囉光偉%鬍小萍%萬軍%夏倩%陳菁%袁文勝%孫潔民
양석%라광위%호소평%만군%하천%진정%원문성%손길민
射干麻黄汤%支气管哮喘%肺通气功能%中西医结合疗法
射榦痳黃湯%支氣管哮喘%肺通氣功能%中西醫結閤療法
사간마황탕%지기관효천%폐통기공능%중서의결합요법
Shegan Mahuang decoction%Bronchial asthma%Pulmonary function%Integrative traditional Chinese and western medicine therapy
目的:观察射干麻黄汤中药配方颗粒对哮喘患者的治疗效果。方法采用前瞻性研究方法,将51例轻度哮喘(寒哮)患者按随机数字表法分为治疗组25例和对照组26例。两组常规对症治疗相同,对照组给沙丁胺醇气雾剂,每次吸入100μg,每日4次;治疗组在对照组用药基础上加用射干麻黄汤中药配方颗粒冲服,每日1剂,早晚两次冲服;两组均治疗12周。分别于治疗前后进行哮喘控制测试评分(ACT评分),并检测1秒用力呼气容积(FEV1)、最大呼气峰流速(PEF)水平,观察两组临床疗效及不良反应和依从性。结果治疗组患者病情完全控制水平明显优于对照组(16例比9例,χ2=4.82,P=0.028)。两组治疗后FEV1、PEF及ACT评分均较治疗前明显升高,且以治疗组升高更显著〔FEV1(L):2.67±0.46比2.32±0.47,PEF(L/min):327.6±49.4比273.1±42.8,ACT评分(分):22.8±2.0比21.1±2.6,均P<0.05〕,治疗组治疗后FEV1%预计值较治疗前升高,对照组较治疗前降低,治疗后两组比较差异有统计学意义(0.68±0.07比0.80±0.11,P<0.05),两组均无明显不良反应,患者依从性较好。结论射干麻黄汤中药配方颗粒能有效改善哮喘患者的临床症状、肺功能及控制水平,有助于哮喘病情的控制。
目的:觀察射榦痳黃湯中藥配方顆粒對哮喘患者的治療效果。方法採用前瞻性研究方法,將51例輕度哮喘(寒哮)患者按隨機數字錶法分為治療組25例和對照組26例。兩組常規對癥治療相同,對照組給沙丁胺醇氣霧劑,每次吸入100μg,每日4次;治療組在對照組用藥基礎上加用射榦痳黃湯中藥配方顆粒遲服,每日1劑,早晚兩次遲服;兩組均治療12週。分彆于治療前後進行哮喘控製測試評分(ACT評分),併檢測1秒用力呼氣容積(FEV1)、最大呼氣峰流速(PEF)水平,觀察兩組臨床療效及不良反應和依從性。結果治療組患者病情完全控製水平明顯優于對照組(16例比9例,χ2=4.82,P=0.028)。兩組治療後FEV1、PEF及ACT評分均較治療前明顯升高,且以治療組升高更顯著〔FEV1(L):2.67±0.46比2.32±0.47,PEF(L/min):327.6±49.4比273.1±42.8,ACT評分(分):22.8±2.0比21.1±2.6,均P<0.05〕,治療組治療後FEV1%預計值較治療前升高,對照組較治療前降低,治療後兩組比較差異有統計學意義(0.68±0.07比0.80±0.11,P<0.05),兩組均無明顯不良反應,患者依從性較好。結論射榦痳黃湯中藥配方顆粒能有效改善哮喘患者的臨床癥狀、肺功能及控製水平,有助于哮喘病情的控製。
목적:관찰사간마황탕중약배방과립대효천환자적치료효과。방법채용전첨성연구방법,장51례경도효천(한효)환자안수궤수자표법분위치료조25례화대조조26례。량조상규대증치료상동,대조조급사정알순기무제,매차흡입100μg,매일4차;치료조재대조조용약기출상가용사간마황탕중약배방과립충복,매일1제,조만량차충복;량조균치료12주。분별우치료전후진행효천공제측시평분(ACT평분),병검측1초용력호기용적(FEV1)、최대호기봉류속(PEF)수평,관찰량조림상료효급불량반응화의종성。결과치료조환자병정완전공제수평명현우우대조조(16례비9례,χ2=4.82,P=0.028)。량조치료후FEV1、PEF급ACT평분균교치료전명현승고,차이치료조승고경현저〔FEV1(L):2.67±0.46비2.32±0.47,PEF(L/min):327.6±49.4비273.1±42.8,ACT평분(분):22.8±2.0비21.1±2.6,균P<0.05〕,치료조치료후FEV1%예계치교치료전승고,대조조교치료전강저,치료후량조비교차이유통계학의의(0.68±0.07비0.80±0.11,P<0.05),량조균무명현불량반응,환자의종성교호。결론사간마황탕중약배방과립능유효개선효천환자적림상증상、폐공능급공제수평,유조우효천병정적공제。
Objective To observe the therapeutic effect of traditional Chinese medicine(TCM)granules made by the formula of Shegan Mahuang decoction for treatment of patients with asthma. Methods A prospective study was conducted,51 cases of light to moderate asthma(cold type)patients were randomly divided into treatment group (25 cases)and control group(26 cases). Conventional symptomatic treatments were of the same in two groups. The patients in control group were given salbutamol aerosol inhalation,100μg each time,4 times per day;based on the treatment of the control group,additionally the above mentioned TCM granules dissolved in water was administered orally 1 dose/day taken twice once in the morning and another once in the evening in treatment group. The therapeutic course was 12 weeks in both groups. Before and after treatment,the asthma control test(ACT)score,forced expiratory volume in 1 second(FEV1)and peak expiratory flow(PEF)were observed. The therapeutic effect,adverse reaction and compliance were evaluated. Results The number of patients with asthma completely controlled in the treatment group was significantly higher than that in the control group(16 cases vs. 9 cases,χ2=4.82,P=0.028). In the patients of two groups,FEV1,PEF and ACT scores were significantly improved after treatment,and in the treatment group,they were obviously higher than those in control group〔FEV1(L):2.67±0.46 vs. 2.32±0.47,PEF(L/min):327.6±49.4 vs. 273.1±42.8,ACT score:22.8±2.0 vs. 21.1±2.6,all P<0.05〕. After treatment,FEV1%predicted value was increased in the treatment group but decreased in control group,there was significantly statistical difference〔(0.68±0.07)% vs.(0.80±0.11)%,P<0.05〕,no significant adverse reaction was found,compliance was good. Conclusion TCM granules made by formula of Shegan Mahuang decoction can improve the clinical symptoms, pulmonary function and control level in patients with asthma,so it is an effective medicine for the control of asthma.